Division of Hematology-Oncology, Department of Medicine, Tufts Medical Center, Boston, MA, USA.
Department of Medicine, Boston University School of Medicine, Boston, MA, USA.
BMC Cancer. 2022 May 14;22(1):544. doi: 10.1186/s12885-022-09637-7.
Cancer antigen 125 (CA125) is clinically used to monitor response to therapy in ovarian cancer and has been proposed for use in detecting ovarian cancer. This population-based study examines how demographic characteristics, gynecologic/reproductive history, chronic non-malignant medical conditions, history of non-ovarian cancer, lifestyle practices, and biomarkers of inflammation correlate with serum CA125 in both premenopausal and postmenopausal women without ovarian cancer across the United States.
Participants were identified from the National Health and Nutrition Examination Survey 2001-2002. Linear and logistic regression models were applied.
Higher CA125 levels were found to correlate with younger age, Non-Hispanic White race/ethnicity, and lower body mass index. In premenopausal women (N = 1157), current smoking was associated with lower CA125 (- 24.95%, p = 0.008), and history of non-ovarian cancer was associated with higher CA125 (40.64%, p = 0.045) by multivariable linear regression; both current smoking (odds ratio (OR) = 0.42, p = 0.043) and oral contraceptive pill (OCP) use of 5-10 years (OR = 0.31, p = 0.032) were less likely to be associated with having CA125 level ≥ 35 U/ml by multivariable logistic regression. In postmenopausal women (N = 1116), coronary artery disease (CAD) history was associated with higher CA125 (28.27%, p = 0.047) by multivariable linear regression; history of CAD (OR = 5.00, p = 0.011), history of breastfeeding (OR = 2.46, p = 0.026), and increased CRP level (OR = 1.41, p = 0.042) were more likely to be associated with having CA125 level ≥ 35 U/ml by multivariable logistic regression.
Results suggest CA125 is lower in premenopausal women who are current smokers and OCP users of moderately longer duration but higher in those with non-ovarian cancer. CA125 is higher in those postmenopausal women with CAD, history of breastfeeding and elevated CRP level. These associations can inform clinical interpretation of individual patients' CA125 levels.
癌抗原 125（CA125）临床上用于监测卵巢癌治疗反应，也被提议用于检测卵巢癌。本研究通过基于人群的研究，在美国无卵巢癌的绝经前和绝经后女性中，探讨了人口统计学特征、妇科/生殖史、慢性非恶性医学状况、非卵巢癌病史、生活方式实践和炎症生物标志物与血清 CA125 之间的相关性。
参与者从 2001-2002 年国家健康和营养检查调查中确定。应用线性和逻辑回归模型。
结果发现，CA125 水平与年龄较小、非西班牙裔白人种族/民族和较低的体重指数呈正相关。在绝经前妇女（N=1157）中，当前吸烟与 CA125 水平降低有关（-24.95%，p=0.008），而非卵巢癌病史与 CA125 水平升高有关（40.64%，p=0.045）；多变量线性回归；当前吸烟（比值比（OR）=0.42，p=0.043）和使用 5-10 年避孕药（OR=0.31，p=0.032）与 CA125 水平≥35 U/ml 的可能性降低有关多变量逻辑回归。在绝经后妇女（N=1116）中，冠心病（CAD）病史与 CA125 水平升高相关（多变量线性回归，p=0.047）；CAD 病史（OR=5.00，p=0.011）、母乳喂养史（OR=2.46，p=0.026）和 CRP 水平升高（OR=1.41，p=0.042）与 CA125 水平≥35 U/ml 相关的可能性更高多变量逻辑回归。
结果表明，绝经前女性中，当前吸烟者和使用避孕药时间较长者的 CA125 水平较低，但非卵巢癌患者的 CA125 水平较高。绝经后妇女的 CA125 水平较高，这些妇女患有 CAD、有母乳喂养史和 CRP 水平升高。这些关联可以为临床解释个体患者的 CA125 水平提供信息。
